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1.23 95%CI -1.35-1.11, P0.00001), TG (WMD-0.50, 95%CI -0.73-0.27,
P0.00001); and statinmetforminwasmore effective thanmetformin in lowering
LDL (WMD--0.84, 95%CI: -1.33-0.354, P0.0009), TC (WMD-1.28, 95%CI:
-1.47-1.10 P0.00001), and TG (WMD-0.27, 95%CI: -0.36-0.19, P0.00001). Het-
erogeneities were detected during the meta-analysis. CONCLUSIONS: Statins can
positively reduce the concentration of total testosterone, TC, TG and LDL. It cannot
be concluded, however, that statins have the long-term benefit. A large-scale, well-
designed, randomized controlled study is needed to ascertain this uncertainty.
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OBJECTIVES: To describe characteristics of T2DM patient subgroups who were more
likely to achieve HbA1c goal 7%with combination treatment of DPP4i with PIO orwith
METusingapredictivemodel.METHODS: Stepwise logistic regressionwas applied to
MarketScan claims data to develop a predictive model that estimated the proba-
bilities of HbA1c goal achievement in patients receiving DPP4i combinations. Sam-
ple selection criteria included: 1) T2DM diagnosis; 2) treatment of DPP4i with PIO or
with MET; 3) baseline HbA1c  7%; and 4) with one-year continuous enrollment.
Patients were ranked by the probabilityof achieving HbA1c7% and grouped into
cumulative percentiles; baseline characteristics of the optimal subgroups identi-
fied as the first 20th and 80th percentiles were reported. RESULTS: A total of 328
patients were included. The predictive model showed that patients who had neu-
ropathy, cerebrovascular conditions, or higher total medication use at baseline
were less likely to achieve goal on DPP4i combinations while patients with self
monitoring blood glucose use at baselineweremore likely to achieve goal (P 0.05).
The 80th percentile subgroup (n270) had a goal reaching rate of 57.0%,mean age of
50.3 years old, 44.3% female, 38.5% on MET, 13.8% on thiazolidinedione (TZD), and
HbA1c  9.13% at baseline. The 20th percentile subgroup (n83), achieved goal at
the rate of 72.3%, mean age of 50.6 years old, 46.1% female, 53.9% onMET, 25.7% on
TZD, and HbA1c  8.96% at baseline. CONCLUSIONS: Predictive factors for reaching
goal include: 1) use of self monitoring blood glucose, and 2) lack of neuropathy, cerebro-
vascular disease, or usage of medications. Subgroups that might benefit the most from
DPP4i treatment were identified. These patients exhibited a higher likelihood of having
prior use ofMET or TZD, and baseline HbA1c less than 9.0%.
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NETWORK META-ANALYSIS OF FIXED DOSE COMBINATION THERAPIES FOR
THE FIRST-LINE TREATMENT OF TYPE 2 DIABETES MELLITUS
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Heron Health Pvt. Ltd., Chandigarh, India
OBJECTIVES: To assess the relative efficacy and safety of fixed dose combinations
(FDCs) of anti-diabetic drugs in treatment naïve patients with type 2 diabetes mel-
litus (T2DM) using networkmeta-analysis technique.METHODS: Randomized con-
trolled trials, evaluating FDCs in treatment naïve patients with T2DM were
searched via Embase® and MEDLINE®. The abstracts were reviewed and data ex-
tractions were conducted by two independent reviewers. The outcomes of interest
included reduction in Hb1Ac levels, patients with HbA1c7%, fasting plasma glu-
cose (FPG) levels, and incidence of hypoglycemia. A network meta-analysis using
WinBUGS® was performed to combine the reported direct and indirect evidence
and a probability ranking for the included combinations was generated. RESULTS:
Eleven trials (n5781 patients) comparing the following FDCs: sulfonylureas/bigua-
nides (SUL/BGU), thiazolidinediones/biguanides (TZD/BGU), dipeptidyl peptidase-4
inhibitors/biguanides (DPP-4/BGU), alpha-glucosidase inhibitors/biguanides (AGI/
BGU), and thiazolidinediones/sulfonylureas (TZD/SUL) were included. Following
network meta-analysis using BGU, TZDs, and SUL as common comparators, TZD/
SUL was observed to be significantly better in terms of patients with HbA1c7%
than other FDCs [relative risk; 95% credible intervals vs. SUL/BGU (1.16; 1.03-1.3), vs.
TZD/BGU (1.12; 1.01-1.24), and DPP-4/BGU (1.18; 1.07-1.29)]. Statistically, however,
non-significant differenceswere observed among the FDCs other than TZD/SUL for
this outcome. All FDCs achieved clinically meaningful reductions in HbA1c and
FPG, though the differences between the FDCs were statistically non-significant.
According to the probability ranking for reduction in HbA1c and FPG levels, the
rank favored TZD/SUL followed by AGI/BGU, TZD/BGU, SUL/BGU, and DPP/BGU.
The probability of occurrence of hypoglycemia was highest with SUL/BGU (78.3%)
followed by TZD/SUL (20.2%), TZD/BGU (0.03%), and DPP-4/BGU (0.005%). Incidence
of hypoglycemiawas not reported for AGI/BGU. CONCLUSIONS: Clinically, all FDCs
effectively achieved glycemic control in patients with T2DM, however, the risk
ratios from network meta-analysis were inconclusive to determine the relative
efficacy of these FDCs. The probability ranking suggested the potential use of TZD/
SUL in treatment naïve T2DM patients.
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OBJECTIVES: Obesity and type 2 diabetes mellitus (T2DM) are major health issues
in developing countries contributing to increased morbidity and mortality. Bariat-
ric surgery is an effective procedure leading to durable weight loss in morbidly
obese patients, while metabolic surgery aims at resolving T2DM. The objective of
our study was to assess the efficacy and safety of those procedures in Indians.
METHODS: A comprehensive search was performed in PUBMED and websites of
Indian medical databases and journals (www.indmed.org, www.dmri.in, www.n-
mji.in, www.japi.in). Studiesmet the inclusion criteria if they enrolled Indian obese
patients with or without T2DM undergoing following laparoscopic procedures:
sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric banding, single-
incision sleeve gastrectomy. RESULTS: Our search retrieved nine studies (978 pa-
tients) of which three included T2DM patients (N  91) exclusively. Postoperative
excessive weight loss ranged from 59.1% to 76.1% after 12-months and from 65.2%
to 71.1% after 24-months of follow-up. BMI was reduced by 5.9-20.5 kg/m2, dyslip-
idemia was resolved in 34-100% patients and hypertension was improved in 67-
95% individuals around one year after surgery. Moreover, at the same time joint
pain was reduced in 57-97% patients and sleep apnea in 100% subjects. The inci-
dence of asthma and depression were also reduced following bariatric/metabolic
surgery.Metabolic procedures carried out in the subset of diabeticswere associated
with T2DM resolution in 61-100% of patients, reduction of HbA1c by 2.3-4.0 per-
centage points and improvement in fasting blood glucose by 60-144 mg/dl. Reduc-
tion of BMI among diabetics was in the range between 5.9–9.8 kg/m2. Rates of
postoperative complications were generally low and only one death was reported
due to pulmonary embolism. CONCLUSIONS: Bariatric and metabolic procedures
are effective in both weight reduction as well as improvement or resolution of
T2DM. Those procedures are safe and beneficial in morbidly obese patients espe-
cially with T2DM.
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OBJECTIVES: Many studies have shown the distance from skin to muscle layer is
shorter than imagined; it’s important to ensure insulin injections are consistently
made into subcutaneous layer, without leakage/backflow or subject-reported in-
jection pain. The objective of this study was to assess clinical outcomes in T2DM
patients switched from insulin injection with longer pen needles (PNs) to shorter
PNs. METHODS: A retrospective study was conducted from July ’09 to Jan ’12 to
compare lipohypertrophy, bleeding, bruising, insulin leakage, pain, and bulge on
skin in a clinic in Yilan, Taiwan. Eighty-two patients with diabetes who were pre-
scribed injectable insulin were included. Before Jul ’09, all patients were prescribed
8 mm PNs. There was no limitation of insulin type, dosage, gender or education
level. From July 2009 to August 2011, PN length was switched to 5mm, then (begin-
ning Jul ’11) to 4mm. Injection techniques and injection areas were inspected by
certified diabetes educators every 3 months for all subjects. Standard injection
technique were taught and followed-up in patients. All statistical analyses were
conducted using SAS software (vs. 9.1).RESULTS:Demographic characteristics: age
60.514.3 years, 58.5% males, 92.7% T2DM, diabetes duration 16.07.0 years and
insulin injection duration 6.84.2 years. A1C: 8.31.5%, 8.11.2% and 8.11.1%
(p0.3180); BMI: 25.33.4kg/m2, 25.13.4kg/m2 and 25.435.4kg/m2 (p0.8565).
The bleeding/bruising decreased from 64.6% to 56.1% to 54.9% (p0.0904), lipohy-
pertrophy formation decreased from 26% to 20% to 15% (p 0.1954). Reports of
insulin leakage from tip or skin (p0.8715, 0.5644), pain perception (p0.1379) and
bulge on skin (p0.8039) were not statistically significant between 5mm and 4mm
PNs. CONCLUSIONS: No significant changes in A1C and BMI associated with
change in needle length from 8mm to 5mm and from 5mm to 4mmwere observed.
Therewas no apparent increase in leakage of insulin. A trend towards less bleeding
and pain was observed when using shorter needles.
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OBJECTIVES: Exenatide is a new antidiabetic agent which is an analog of incretin
(glucagon-like peptide 1) with a adjunctive therapy with type 2 diabetes mellitus
(T2DM),and has adverse events of nausea, vomiting and poor appetite. To assess
the clinical efficacy of exenatide in T2DM.METHODS: Inclusion criteria were T2DM
with inadequate glycemic control under oral antidiabetic agnets or insulin therapy.
Exenatide were added on by the reatment course of exenatide is 5g twice a day at
first month and then adjusted to 10g twice a day if tolerated. The primary out-
comes are influence on HbA1C level and body weight. RESULTS: Eighteen patients,
who were 7 male and 11 female with mean age of 43.46, were recruited. Of them
had a mean body weight of 97.15kg and mean HbA1C of 9.1%. HbA1c improved
significantly after 3 months and 6 months with mean reduction of 0.75%(p0.002)
and 0.97%(p0.009). Mean body weight mild decreased at 3 months (4.33 kg) and
reduced significantly at 4 months and 6 months with 5kg (p0.005) and 9.74kg
(p0.0006). CONCLUSIONS: Exenatide improve HbA1c and body weight greatly
within 6months in a local hospital andmayhave great affect on the changing of life
style, like diet control and frequency of Self-Monitoring of Blood Glucose. In future,
a larger and long time study would need to demonstrate the validity of exenatide
on the taiwanese.
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OBJECTIVES: Diabetes is a serious, costly metabolic disorder with a rising preva-
lence worldwide. Chromium has long been shown to improve insulin sensitivity,
lipid profiles, and blood glucose in insulin resistance and type-2 diabetic patients.
METHODS: All relevant databases were searched up to December 2011 limited to
human studies in English language. Clinical studies in newly onset patients with
type-2 diabetes reporting use of chromium at least for 4 weeks and outcomes of
fasting blood glucose (FBG), hemoglobin A1C (HbA1c), triglyceride (TG), low density
lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL) and body
mass index (BMI) were identified. Data of before and after use of chromium intake
were compared. RESULTS: The functional outcome data from clinical studies re-
vealed that our of 834 studies, 39 met inclusion criteria. Seventy present of articles
demonstrated a decrease in FBS while 23% showed an increase. Forty-seven per-
cent of studies showed an increase in HbA1c, while 15% a decrease. TG in 60% of
studies showed an increase while in 15% a reductionwas reported. LDL cholesterol
in 60% of studies showed a decrease and in the rest there was no report of increase.
Forty percent of studies showed a decrease in HDL cholesterol while 30% showed
an increase. BMI in 40% of studies decreased and in 7% of cases increased.
CONCLUSIONS: In clinical studies, average of mentioned parameters were im-
proved significantly after administration of chromium in patients with type 2 dia-
betes in a dose-dependent manner with no side effects. This systematic review
indicates beneficial effects of chromium in diabetic patients.
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OBJECTIVES: Growing rates of obesity and type 2 diabetes mellitus (T2DM) are
major health problems in China. Bariatric surgery is an effective treatment for
patientswith clinically severe obesity additionally improving co-morbidities, while
metabolic surgery is a procedure aimed at resolution of T2DM. The main objective
of our study was to assess the efficacy of both procedures performed on Chinese
population. METHODS: A comprehensive search was performed in PUBMED and
websites of Chinesemedical databases and journals including: www.wanfangdata.
com, www.cqvip.com, www.cnki.net, www.docin.com, wenku.baidu.com. Studies
met the inclusion criteria if they enrolled obese Chinese patients with or without
T2DM undergoing following laparoscopic procedures: sleeve gastrectomy, Roux-
en-Y gastric bypass, adjustable gastric banding, single-incision sleeve gastrectomy.
RESULTS:Our search retrieved 17 studies (2339 patients) of which 7 included T2DM
patients (N  374) exclusively. Overall, mean BMI reduction one year following
surgery ranged from 5.7 to 16.8 kg/m2. Excessive weight loss ranged between 25.4-
81.25% and 18.4-72.2%, after 1st and 2nd year of follow-up, respectively. Moreover, 2
years following surgery hypertension resolved in 9-98% of patients, hyperlipidemia
in 42-100%, arthralgia in 90% and sleep apnea in 68-100%. In the subset of diabetes
patients resolution of T2DM was observed in 33%-93% individuals 1 year post-
surgery. In the same timemean HbA1c was improved by 1.2-4.4 percentage points,
FBG was reduced by 37.8-107.2 mg/dl and BMI declined by 5.7-7.1 kg/m2. Bariatric
procedures led to complication rates ranging from 0 to 23.5% during the first post-
operative year and from 5 to 57% during the second year. Reported mortality was
low and did not exceed 0.47%. Additionally, surgery had beneficial effect on pa-
tients’ quality of life, which improved especially in physical, emotional and social
domains. CONCLUSIONS: Bariatric surgery is effective in achieving durable weight
loss and as well as improvement or resolution of T2DM and other co-morbidities.
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OBJECTIVES: Hypertension and obesity are associated with long-term complica-
tions of type 2 diabetes mellitus (T2DM). A systematic literature review assessed
the prevalence of these comorbidities in adults with T2DM in Asia. METHODS:
Electronic databases (PubMed, Embase, Cochrane Library) were searched for pub-
lications related to T2DM plus hypertension and/or obesity (English, 2001-2011).
Bibliographies of included studies were also examined. RESULTS:Of 2303 abstracts
identified, 38 observational studies presented relevant data across 14 countries/
regions in Asia. Prevalence rates reported here are for adults with T2DM. In China,
hypertension prevalence was 49.9%-60.6% when hypertension was defined by
blood pressure cutpoints of 140/90 mmHg and/or use of antihypertensive medi-
cine,whereas the prevalencewas 74.7%-76.5%whenblood pressure cutpointswere
reduced to 130/85. A study in Israel using cutpoints of 140/90, 130/85, and
130/80 mmHg found hypertension prevalence rates of 60.2%, 76.5%, and 85.8%,
respectively. In studies reporting prevalence by a single hypertension definition,
the prevalence rates ranged from 61.0% to 78.1% when the cutpoints were130/80
or 130/85 mmHg and 13.6% to 78.4% when the cutpoints were 140/90 mmHg.
Obesity prevalence data were limited. Cutpoints for defining obesity by body mass
index (BMI) or waist circumference (WC) varied among the studies. The obesity
prevalence rates by BMI were: Israel, 20.1%; Japan, 33.9%; Qatar, 53.8%; Taiwan,
38%-52.7%; Jordan, 58.6%; Saudi Arabia, 83.4%; Iran, 85.5%; and byWCwere: Japan,
24.3%-27.0%; South Korea, 37.2%; Pakistan, 61.5%; India, 67%. Few studies reported
comorbidity of both hypertension and obesity, with varying definitions of each
comorbidity. The prevalence of hypertension with obesity was: Saudi Arabia,
10.7%; Japan, 18.0%-20.6%; Jordan, 76.6%; Israel, 69.7%-93.3%. CONCLUSIONS: In
Asians, hypertension and obesity, separately or together, are common comorbidi-
ties of T2DM. Accurate, consistent reporting of their prevalence will help quantify
efforts needed to manage these comorbidities and their long-term health and cost
consequences.
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A1C VARIABILITY IS ASSOCIATED WITH THE RISK OF DEVELOPING NEW
DIABETES FOR THE HEALTHY ADULTS
Takahashi O
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OBJECTIVES:The association of A1C’s variabilitywith developing newdiabetes has
been little studied. We aimed to evaluate the effect of visit-to-visit A1C variability
on the risk of developing new diabetes in healthy adults in Japan. METHODS:
Population-based, cohort study from 2005 to 2008 in Tokyo, Japan of healthy adults
not taking diabetes medication and with a HbA1c lower than 6.5% at baseline.
Based on annual measurement of serum HbA1c we calculated the annual visit-to-
visit variability, and used this as a predictor of new onset diabetes in amultivariate
logistic regression. RESULTS: At baseline, 14,587 people (50% female) with a mean
age of 51 years old (SD: 12 years, range: 23 to 92), a mean fasting plasma glucose
(FPG) level of 98.4 mg/dl (SD: 9.3 mg/dl) and a mean HbA1c level of 5.3 % (SD: 0.4 %)
had annual check-ups over 4 years. After adjusting for the other potential risk
factors new diabetes was predicted by the A1C variability (odds ratio (OR): 10.3 for
highest ( 0.16%)) versus the lowest quantile (0.08 %), 95%CI: 5.9 – 18.0) and by
the baseline A1C (OR: 55.2 for A1C of 6.0 – 6.4 % versus A1C of 5.0 %, 95% CI: 13.2
– 230). FPG (OR: 1.1, 95%CI: 1.1 – 1.2) and Smoker (OR: 1.8, 95%CO: 1.3 – 2.6) weakly
but also significantly related to develop the new diabetes. For predicting the devel-
opment of diabetes, the combination of the level of AIC at baseline and the vari-
ability (AUC for the ROC0.94) was superior to the level of A1C at baseline alone
(AUC0.89). CONCLUSIONS: Visit-to-visit variability in A1C independently added
to the baselineA1C in predicting the risk of developing newdiabetes for the healthy
adults. We should consider not only the baseline A1c level but also variability in
A1C to prevent development of the diabetes.
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OBJECTIVES:The FDAwarned on June 15, 2011 of the bladder cancer risk associated
with pioglitazone use. Therefore, we conducted a retrospective review of pioglita-
zone use in our hospital, to find out high risk patient, provide FDA safety advice by
using electronic message in computerized physician order entry system (CPOE),
aim to ensure physician aware of the risk at the moment of patient clinic visit.
METHODS: We included outpatients with pioglitazone use from January 1, 2006
through July 31, 2011. For high risk patients, who are male, prescribed pioglitazone
more than 1 year and cumulative dose reached 28000mg, clinical pharmacists will
established warning message in CPOE. The message was to inform physician the
patient was at high risk for bladder cancer, and should care about the symptoms of
bladder cancer, such as hematuria; urgent need to urinate or pain while urinating;
pain in back or lower abdomen. RESULTS: Overall 3196 patients had ever pre-
scribed pioglitazone. The mean age was 63.2  11.9 years, and 1519 (49%) of the
patients were male. Five (0.16%) patients with the diagnosis of bladder cancer.
There were 1874 patients with currently pioglitazone use, 629 (33.5%) patients pre-
scribed pioglitazonemore than 1 year, 160 (8.5%) patients cumulative dose reached
28000mg, and 75 (4%) of our patients were at high risk for bladder cancer. Eighteen
(24%) high risk patients were discontinued pioglitazone after FDA announcement,
another 18 (24%) patients because ofwarningmessage established by clinical phar-
macists. Twenty six (66.7%) patients have urine test, 5 (12.8%) with positive occult
blood. CONCLUSIONS: From the retrospective results, there was no association
between pioglitazone use and bladder cancer in our hospital. The communication
by using electronicmessage in CPOE enhanced the awareness of physician. Clinical
pharmacistswill prospectively establish thewarningmessage for patientwith high
risk.
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COMPARISON OF CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH
DPP4 INHIBITORS (DPP4I) VERSUS SULFONYLUREA (SU) IN COMBINATION
WITH METFORMIN (MET) OR PIOGLITAZONE (PIO) FOR THE TREATMENT OF
TYPE 2 DIABETES MELLITUS (T2DM)
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OBJECTIVES: To compare diabetes-related complications, utilizations and costs
between diabetes patients treated with DPP4i-based combinations (DPP4iMET or
DPP4iPIO) vs. SU-based combinations (SUMET or SUPIO).METHODS: Market-
Scan, a U.S. database of insured members, was analyzed to retrospectively com-
pare outcomes between patients treated with DPP4i and SU combinations. The
study sample consisted of T2DM patients who received DPP4i or SU combinations
and had continuous eligibility from 6months prior to and 12months following the
index date (date of combination therapy initiation). Rates of diabetic complica-
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